Big Pharma’s lobbying organization, BIO, vehemently denies authoring a controversial memo outlining plans to separate Robert F. Kennedy Jr. from President Trump’s administration, while simultaneously claiming alignment with their “Make America Healthy Again” initiative.
Key Takeaways
- A leaked memo, allegedly from the Biotechnology Innovation Organization (BIO), outlined plans to separate RFK Jr. from Trump’s administration due to his vaccine stance.
- BIO adamantly denies creating the document while simultaneously claiming alignment with Kennedy’s “Make America Healthy Again” (MAHA) agenda.
- The contested document details a “Why We Vaccinate” promotional campaign targeting conservatives and aiming to distance Kennedy from Trump.
- MAHA focuses on preventive care, vaccine transparency, environmental health, and integrative medicine to address chronic diseases and healthcare costs.
- Multiple sources provide conflicting accounts regarding the memo’s authenticity, fueling ongoing controversy.
Disputed Memo Creates Healthcare Policy Controversy
A firestorm of controversy has erupted over a leaked document purportedly from the Biotechnology Innovation Organization (BIO), a major pharmaceutical industry lobbying group. The memo, published by the Brownstone Institute, appears to detail strategies for distancing Health and Human Services Secretary Robert F. Kennedy Jr. from President Trump’s administration due to Kennedy’s well-known vaccine safety concerns. Despite the document’s specific details, BIO has categorically denied its authenticity, creating a puzzling contradiction that has conservatives questioning the pharmaceutical industry’s true agenda regarding the Trump administration’s health initiatives.
The disputed memo describes plans for a “Why We Vaccinate” campaign aimed at promoting vaccine acceptance, particularly among conservative audiences. It reportedly mentioned several prominent figures for potential involvement, including Dr. Mehmet Oz, former FDA Commissioner Scott Gottlieb, and former Senators Richard Burr and Bill Cassidy. If authentic, the document reveals a coordinated effort to influence public opinion on vaccines while simultaneously working to undermine Kennedy’s position in the administration – a concerning revelation for supporters of medical freedom and transparency that Kennedy champions.
— P a u l ◉ (@SkylineReport) May 9, 2025
BIO’s Contradictory Response Raises Questions
In an official statement addressing the controversy, BIO emphatically denies any involvement with the memo while simultaneously claiming alignment with Kennedy’s health initiatives. “Earlier today, a blog site posted an article based on what it claimed was a leaked memo from BIO regarding our Vaccines Task Force. The purported memo was not produced by BIO. We have never seen or heard of this document, and it certainly does not accurately represent the spirit, strategy, or mission of BIO’s work,” said a BIO spokesman.
“We are aligned with Health and Human Services Secretary Kennedy and the President’s mission to ‘Make America Healthy Again.’ We also believe strongly in the vital role that vaccines play for public health, and we will continue to be strong advocates for scientific rigor and the importance of vaccines to protect our children, our citizens broadly—and to protect and strengthen America,” a BIO spokesman stated in response to inquiries about the controversial document.
Despite BIO’s denials, BioCentury, a biotech industry publication, reportedly confirmed the memo’s description of an April 3 meeting while stating that BIO does not plan to lobby against Kennedy. This contradiction between public statements and reported confirmations only deepens the mystery surrounding the document’s origins and authenticity. For conservative supporters of the Trump administration’s health reform efforts, these conflicting narratives suggest potential behind-the-scenes resistance to Kennedy’s reform agenda from pharmaceutical interests.
Make America Healthy Again: Revolutionary Health Policy Approach
The “Make America Healthy Again” initiative represents one of the Trump administration’s most significant health policy innovations. MAHA focuses on preventive care, vaccine transparency, environmental health, and integrative medicine approaches to tackle chronic diseases and reduce healthcare costs. The program specifically addresses America’s growing chronic disease crisis, particularly among children, through promoting healthy lifestyles, better nutrition, and reduced exposure to environmental toxins that contribute to illness.
Brownstone published the document with all provisos concerning its provenance. The statement from BIO that it supports RFK’s MAHA agenda is, of course, welcome,” said Jeffrey Tucker, commenting on BIO’s response to the controversy.
Kennedy’s commitment to “vaccine transparency” has been a cornerstone of his health policy approach, focusing on informed consent and safety oversight that resonates strongly with many conservative voters tired of big government and corporate control over healthcare decisions. The initiative also tackles rural healthcare challenges through student loan forgiveness programs for providers serving underserved areas, telehealth investments, and upgrading medical facilities in rural communities, addressing longstanding Republican concerns about healthcare access in red states.
Industry Concerns Revealed
The disputed document highlights pharmaceutical industry concerns about investor confidence in vaccine development and the unpredictability of the approval process under the current administration. According to the memo, former FDA Commissioner Scott Gottlieb allegedly described the MAHA movement as a cover for an anti-vaccine campaign and emphasized the importance of differentiating between vaccine hesitancy and groups opposed to vaccine mandates – a distinction that many conservatives find disingenuous given their fundamental concerns about medical freedom and government overreach.
Jeffrey Rose, a MAHA Institute volunteer, believes the document is authentic and criticizes what he sees as the pharmaceutical industry’s potential undermining of Kennedy’s efforts. This perspective resonates with many Trump supporters who view the pharmaceutical industry as part of the “deep state” that has consistently opposed President Trump’s efforts to reduce drug prices and increase healthcare transparency. The controversy highlights the ongoing tension between corporate healthcare interests and the administration’s reform agenda.
Regardless of the memo’s authenticity, the MAHA initiative continues to advance its core mission of addressing chronic disease through preventive approaches and transparent healthcare practices. An executive order establishing the MAHA Commission stated that current health trends “harm us, our economy, and our security” and aims to “re-direct” healthcare priorities toward prevention and wellness – a policy direction that represents a clear break from the pharmaceutical-dominated approach of previous administrations and offers renewed hope for Americans suffering under the burden of chronic illness and skyrocketing healthcare costs.
